Encapsulation of Curcumin Within Poly(amidoamine) Dendrimers for Delivery to Cancer Cells

Overview

Journal J Mater Sci Mater Med

Publisher Springer

Specialty Biomedical Engineering

Date 2013 Jun 20

PMID 23779153

Citations 15

Authors

Lu Wang

Xiaoping Xu

Yi Zhang

Yuanqing Zhang

Ying Zhu

Jiye Shi

Yanhong Sun

Qing Huang

Affiliations

Soon will be listed here.

Abstract

Curcumin has anti-proliferative and pro-apototic properties against a variety of cancer cells in vitro. Unfortunately, the water-insolubility and instability leads to its low bioavailability in vivo tests. Here, we report a general approach to using poly(amidoamine) dendrimer with acetyl terminal groups to encapsulate curcumin(G₅-Ac/Cur) for drug delivery to cancer cells. The solubility, release kinetics, anticancer activity, and apoptotic-related protein expression (Bax and Bcl-2) were investigated in detail. Comparing with curcumin, the water-solubility value of G₅-Ac/Cur increased 200-fold, and the release of curcumin from the complexes was in a sustained manner. G₅-Ac/Cur showed higher anti-proliferative activity against A549 cell lines and had the better effect on the generation of intracellular reactive oxygen species, the mitochondrial membrane potential and cell apoptosis. Furthermore, the ratio of Bax/Bcl-2 was higher in samples treated with G₅-Ac/Cur. The results indicated that the G₅-Ac drug delivery system could improve the solubility and anti-cancer effect of curcumin.

Citing Articles

Targeted co-delivery nanosystem based on methotrexate, curcumin, and PAMAM dendrimer for improvement of the therapeutic efficacy in cervical cancer.

Aghanejad A, Kheiriabad S, Ghaffari M, Namvar Aghdash S, Ghafouri N, Ezzati Nazhad Dolatabadi J Sci Rep. 2025; 15(1):1813.

PMID: 39805840 PMC: 11730290. DOI: 10.1038/s41598-024-82074-7.

Curcumin Encapsulation in Aluminum Fumarate Metal-Organic Frameworks for Enhanced Stability and Antioxidant Activity.

Al Azzi P, El Kurdi R, Patra D ACS Omega. 2025; 9(51):50561-50569.

PMID: 39741827 PMC: 11683643. DOI: 10.1021/acsomega.4c08387.

Organic and Biogenic Nanocarriers as Bio-Friendly Systems for Bioactive Compounds' Delivery: State-of-the Art and Challenges.

Petrovic S, Barbinta-Patrascu M Materials (Basel). 2023; 16(24).

PMID: 38138692 PMC: 10744464. DOI: 10.3390/ma16247550.

Smart Targeted Delivery Systems for Enhancing Antitumor Therapy of Active Ingredients in Traditional Chinese Medicine.

Kang C, Wang J, Li R, Gong J, Wang K, Wang Y Molecules. 2023; 28(16).

PMID: 37630208 PMC: 10459615. DOI: 10.3390/molecules28165955.

The Nanotech Potential of Curcumin in Pharmaceuticals: An Overview.

Pardeshi S, Mohite P, Rajput T, Puri A Curr Drug Discov Technol. 2023; 21(2):e260723219113.

PMID: 37493163 DOI: 10.2174/1570163820666230726125809.

References

Chen Q, Wang Y, Xu K, Lu G, Ying Z, Wu L . Curcumin induces apoptosis in human lung adenocarcinoma A549 cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Oncol Rep. 2010; 23(2):397-403. View

Majoros I, Thomas T, Mehta C, Baker Jr J . Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem. 2005; 48(19):5892-9. DOI: 10.1021/jm0401863. View

Boise L, Gonzalez-Garcia M, Postema C, Ding L, LINDSTEN T, Turka L . bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74(4):597-608. DOI: 10.1016/0092-8674(93)90508-n. View

Aggarwal B, Kumar A, Bharti A . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363-98. View

Reuter S, Eifes S, Dicato M, Aggarwal B, Diederich M . Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol. 2008; 76(11):1340-51. DOI: 10.1016/j.bcp.2008.07.031. View

Li L, Braiteh F, Kurzrock R . Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005; 104(6):1322-31. DOI: 10.1002/cncr.21300. View

Thomas T, Majoros I, Kotlyar A, Kukowska-Latallo J, Bielinska A, Myc A . Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem. 2005; 48(11):3729-35. DOI: 10.1021/jm040187v. View

Majoros I, Myc A, Thomas T, Mehta C, Baker Jr J . PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules. 2006; 7(2):572-9. DOI: 10.1021/bm0506142. View

Tang H, Murphy C, Zhang B, Shen Y, Van Kirk E, Murdoch W . Curcumin polymers as anticancer conjugates. Biomaterials. 2010; 31(27):7139-49. DOI: 10.1016/j.biomaterials.2010.06.007. View

10.

Lin H, Kuo L, Chuu C . Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells. Phytother Res. 2011; 26(1):122-6. DOI: 10.1002/ptr.3523. View

11.

Cheng A, Hsu C, Lin J, Hsu M, Ho Y, Shen T . Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21(4B):2895-900. View

12.

Markatou E, Gionis V, Chryssikos G, Hatziantoniou S, Georgopoulos A, Demetzos C . Molecular interactions between dimethoxycurcumin and Pamam dendrimer carriers. Int J Pharm. 2007; 339(1-2):231-6. DOI: 10.1016/j.ijpharm.2007.02.037. View

13.

Farrow S, White J, Martinou I, Raven T, Pun K, Grinham C . Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature. 1995; 374(6524):731-3. DOI: 10.1038/374731a0. View

14.

Barzegar A, Moosavi-Movahedi A . Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PLoS One. 2011; 6(10):e26012. PMC: 3189944. DOI: 10.1371/journal.pone.0026012. View

15.

Yang W, Cheng Y, Xu T, Wang X, Wen L . Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem. 2008; 44(2):862-8. DOI: 10.1016/j.ejmech.2008.04.021. View

16.

Hidaka H, Ishiko T, Furuhashi T, Kamohara H, Suzuki S, Miyazaki M . Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface:impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer. 2002; 95(6):1206-14. DOI: 10.1002/cncr.10812. View

17.

Anand P, Kunnumakkara A, Newman R, Aggarwal B . Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4(6):807-18. DOI: 10.1021/mp700113r. View

18.

Yang E, Zha J, Jockel J, Boise L, Thompson C, Korsmeyer S . Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995; 80(2):285-91. DOI: 10.1016/0092-8674(95)90411-5. View

19.

Dhillon N, Aggarwal B, Newman R, Wolff R, Kunnumakkara A, Abbruzzese J . Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008; 14(14):4491-9. DOI: 10.1158/1078-0432.CCR-08-0024. View

20.

Chen Q, Lu G, Wu Y, Zheng Y, Xu K, Wu L . Curcumin induces mitochondria pathway mediated cell apoptosis in A549 lung adenocarcinoma cells. Oncol Rep. 2010; 23(5):1285-92. DOI: 10.3892/or_00000762. View